Novartis announces findings from a real-world study of alpelisib demonstrating clinical benefit in people with PIK3CA-Related Overgrowth Spectrum (PROS)
- PROS is a spectrum of rare disorders caused by PIK3CA mutations and is characterized by atypical, visible overgrowths and anomalies in blood vessels, the lymphatic system and other tissues
- At 24 weeks, 38% of patients achieved ≥20% reduction in the volume of the PROS lesions assessed in the primary endpoint analysis; no patients experienced disease progression or death
- Alpelisib is the first potential treatment to specifically address the root cause of PROS conditions
- EPIK-P1 study findings presented at ESMO Virtual Congress 2021 support FDA submission
Basel, September 17, 2021— Novartis today announced important findings from a real-world study evaluating the safety and efficacy of alpelisib for people living with PIK3CA-Related Overgrowth Spectrum (PROS) who received treatment daily for at least 24 weeks. Results from EPIK-P1 showed alpelisib effectively reduced volume of clinically significant PROS-related lesions and improved signs and symptoms in pediatric and adult patients. Results were presented at the European Society of Medical Oncology (ESMO) Virtual Congress 2021 [LBA23].
“There are few options available to manage PROS conditions, and they are mainly focused on addressing worsening symptoms. It is devastating for patients to be without treatments that address the underlying cause of PROS,” said Guillaume Canaud, MD, PhD, Necker-Enfants Malades Hospital – AP-HP, the Paris Descartes University, Inserm (INEM Institute Necker Enfants Malades – Centre for Molecular Medicine). “The EPIK-P1 findings show robust clinical benefit for adult and pediatric patients and a potential new path forward for those impacted by PROS conditions.”
In EPIK-P1, alpelisib reduced target lesion volume and improved PROS-related symptoms and manifestations. The primary endpoint analysis conducted at week 24 in patients with complete cases (n=32) showed 38% of patients achieving a response to treatment which was defined as 20% or greater reduction in the sum of PROS target lesion volume. Nearly three in four patients (74%) showed some reduction in target lesion volume, with a mean reduction of 13.7%, and no patients experienced disease progression at time of primary analysis.
Additionally, at week 24, investigators reported patient improvements from baseline in pain (90%), fatigue (76%), vascular malformation (79%), limb asymmetry (69%), and disseminated intravascular coagulation (55%) across the full study population (n=57).
“Thanks to the data from patients and physicians included in the analysis of EPIK-P1, we have findings to help validate the potential of alpelisib in PROS and have taken an important step toward reimagining medicine for the PROS community,” said Jeff Legos, Executive Vice President, Global Head of Oncology & Hematology Development. “We will continue to discuss this real-world evidence with the FDA in an effort to bring this treatment to people in need as quickly as possible.”
Adverse events (AEs) and treatment-related AEs (TRAEs) were experienced by 83% and 39% of patients, respectively. Most AEs were mild to moderate in severity, and there were no AEs leading to treatment discontinuation. The most common AEs of any grade were diarrhea (16%), hyperglycemia (12%), aphthous ulcers (11%), and stomatitis (5%). The most common grade 3/4 AE was cellulitis (4%); one adult case was considered treatment-related.
PROS is a wide-ranging spectrum of disorders caused by a mutation in the PIK3CA gene. PROS conditions are rare and visually diverse, and are typically characterized by atypical growths and anomalies in blood vessels, the lymphatic system and other tissues. PROS conditions can look different from each other in size, shape, and type of growth or malformation based on where in the body the mutation is found.1,2 PROS can disrupt mobility and cognitive function in some patients and may lead to life-threatening complications.3-5
There are no approved medical therapies for PROS conditions. PROS management varies by patient, and surgery and radiologic embolization are common with patients often undergoing multiple procedures due to frequent regrowth following surgery.1,3,4,6-9 There is a significant need for treatment options for PROS that reduce overgrowth, address symptoms, and improve quality of life.3,9-10
The U.S. Food and Drug Administration (FDA) granted alpelisib Breakthrough Therapy Designation on November 13, 2019, and discussions with FDA about alpelisib for PROS are ongoing.
About PIK3CA-Related Overgrowth Spectrum (PROS)
The PROS classification was proposed at the National Institutes of Health in a workshop in 2013 to unite a group of rare overgrowth conditions caused by PIK3CA mutations.1,2 Specific conditions associated with PROS include KTS, CLOVES syndrome, ILM, MCAP/M–CM, HME, HHML, FIL, FAVA, macrodactyly, muscular HH, FAO, CLAPO syndrome and epidermal nevus, benign lichenoid keratosis, or seborrheic keratosis.1,2 The estimated prevalence of PROS conditions is approximately 14 people per million.6 To learn more, visit understandingpros.com.
EPIK-P1 is a global, site-based retrospective non-interventional medical chart review of pediatric and adult male and female patients aged 2 years or older with PIK3CA-Related Overgrowth Spectrum (PROS) who received alpelisib via a compassionate use program. Primary endpoint is proportion of patients with response at 24 weeks, defined as achieving at least 20% reduction from index date in the sum of measurable target lesion volume via central imaging. Data were obtained from medical charts of 57 patients (39 pediatric, 18 adult) at seven sites in five countries. There were 32 complete cases, meaning there were complete scans for comparison at baseline and date of analysis, and one patient discontinued prior to week 24 due to lack of clinical efficacy.
Alpelisib is not approved by any regulatory authority for the treatment of PROS conditions.
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 140 nationalities work at Novartis around the world. Find out more at https://www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnews
For Novartis multimedia content, please visit https://www.novartis.com/news/media-library
For questions about the site or required registration, please contact email@example.com
- Keppler-Noreuil KM, Rios JJ, Parker VER, et al. PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation. Am J Med Genet A. 2015;167A(2):287-295.
- Ko JM. Genetic syndromes associated with overgrowth in childhood. Ann Pediatr Endocrinol Metab. 2013;18(3):101-105.
- Keppler-Noreuil KM, Sapp JC, Lindhurst MJ, et al. Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum. Am J Med Genet A. 2014;164A(7):1713-1733.
- Parker VER, Keppler-Noreuil KM, Faivre L, et al. Genet Med. 2019;21(5):1189-1198.
- Mirzaa G, Conway R, Graham JM Jr, Dobyns WB. PIK3CA-related segmental overgrowth. In: Adam MP, Ardinger HH, Pagon RA, et al, eds. GeneReviews® [Internet]. Seattle, WA: University of Washington, Seattle; 1993-2019.
- Data on file. Novartis Pharmaceuticals Corp; 2020.
- Madsen RR, Vanhaesebroeck B, Semple RK. Cancer-associated PIK3CA mutations in overgrowth disorders. Trends Mol Med. 2018;24(10):856-870.
- Bessis D, Vernhet H, Bigorre M, Quere I, Rossler J. Life-threatening cutaneous bleeding in childhood Klippel-Trenaunay syndrome treated with oral sirolimus. JAMA Dermatol. 2016;152(9):1058-1059.
- Crunkhorn S. Genetic disorders: PI3K inhibitor reverses overgrowth syndrome. Nat Rev Drug Discov. 2018;17(8):545.
- Venot Q, Blanc T, Rabia SH, et al. Targeted therapy in patients with PIK3CA-related overgrowth syndrome. Nature. 2018;558(7711):540-546.
# # #
Novartis Media Relations
| Anja von Treskow |
Novartis External Communications
+41 79 392 86 97
Novartis US External Communications
+1 862 579 8456
| Dan Connelly|
Associate Director, Portfolio Communications
+1 862 210 0217
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
|Samir Shah||+41 61 324 7944||Sloan Simpson||+1 862 778 5052|
| Thomas Hungerbuehler |
| +41 61 324 8425|
+41 61 324 7188
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Mandalay Resources Corporation tillkännager produktions- och försäljningsresultaten för tredje kvartalet 202120.10.2021 04:50:30 CEST | Pressemelding
TORONTO, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation (”Mandalay” eller ”bolaget”) (TSX: MND, OTCQB: MNDJF) tillkännagav idag sina produktions- och försäljningsresultat för tredje kvartalet 2021. Produktionshöjdpunkter för tredje kvartalet 2021: Konsoliderad produktion av säljbara guldekvivalenter på 33 121 uns – högsta kvartalsresultat sedan fjärde kvartalet 2017; Konsoliderad försäljning på 29 752 uns guldekvivalent – högsta kvartalsbeloppet på fyra år; Costerfields högsta kvartalsvisa produktion någonsin av säljbara guldekvivalenter på 18 946 uns; och Cerro Bayo producerade 2 925 uns guldekvivalent. Bolaget förväntar sig att Cerro Bayos totala bidrag kommer att uppgå till 9 000–10 000 uns guldekvivalent i slutet av året. Baserat på de årliga produktionsresultaten förväntar sig Mandalay att den konsoliderade säljbara produktionen 2021 (exklusive produktionen från Cerro Bayo) kommer att ligga i den högre delen av den tidigare tillhandahållna produktionsprognosen på
Jotul Holdings SA to redeem its outstanding up to NOK 400,000,000 senior secured floating rate bonds with ISIN NO001081574919.10.2021 20:00:00 CEST | Press release
Jotul Holdings SA hereby refers to its outstanding up to NOK 400,000,000 senior secured floating rate bonds with ISIN NO0010815749 (the "Bonds") and to the terms and conditions of the Bonds (the "Terms and Conditions"). Reference is further made to a call notice dated 28 September 2021, in which Jotul Holdings SA informed the holders of the Bonds that it was exercising its option to redeem all outstanding Bonds in full pursuant to Clause 9.3 (Voluntary total redemption (call option)) of the Terms and Conditions (the "Call Notice") on 25 October 2021 (the "Redemption Date"). Jotul Holdings SA's obligation to redeem the Bonds on the Redemption Date was conditional upon Jøtul AS fulfilling the conditions precedent for disbursement of the net proceeds from its bonds issued 6 October 2021, which are, among other things, to be applied towards financing the redemption of the Bonds by way of repayment of shareholder loans provided by Jotul Holdings SA (the "Financing Condition"). Jotul Holding
Greenland Resources Appoints Jens Moberg as Senior Advisor19.10.2021 15:57:02 CEST | Press release
TORONTO, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Greenland Resources Inc. (NEO:MOLY, FSE:2LF) (“Greenland Resources” or the “Company”) is pleased to announce that it has created a European Advisory Board with the objective of providing strategic and technical input to corporate decision-making in respect of relevant stakeholders in the European industry ecosystem, with particular reference to the development of the Malmbjerg molybdenum deposit in east Greenland. To this extent, Mr. Jens Moberg will join as Senior Advisor. Jens has over twenty-five years of experience in international executive positions. Currently, he is the Chairman of the Board of Grundfos, a leading pump and water technology company with over 19,000 employees represented in more than 60 countries. He also acts as Member of the Board of Kirk Kapital A/S, a family owned financial investment firm with a heritage that stretches back to the world-famous LEGO name; and as a member of The Poul Due Jensen Foundation Board. To nam
VoltH2 Expands Management Team19.10.2021 15:50:29 CEST | Press release
JERSEY CITY, N.J., Oct. 19, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Vision Hydrogen Corporation (OTCQB:VIHD) (the “Company”) is pleased to announce that VoltH2, a Europe-based developer of green hydrogen production infrastructure projects that is 15.9% owned by the Company, has expanded its management team. VoltH2 continues to make significant progress in realizing its objectives and has made a number of strategic hires, increasing its core team of highly experienced commercial and engineering professionals to 10 individuals, with a plan to double the team headcount by Q2 2022 as the pace of business continues to increase. Since commencing operation in early 2020, VoltH2 has been successfully executing on its mission to design, develop and build scalable hydrogen production facilities at multiple strategic locations in Western Europe. Deploying only proven and commercial technologies in partnership with established energy-industry participants, VoltH2 has been awarded permits for
Benjamin Hill Updates on Planned Inaugural Drill Program With Outline of Prospective Targets19.10.2021 13:30:00 CEST | Press release
VANCOUVER, British Columbia, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Benjamin Hill Mining Corp. (CSE: BNN) (OTCBB: BNNHF) (“BHM” or the “Company”) Benjamin Hill Mining Corp. is pleased to announce that drill locations have been finalized for the upcoming inaugural drill program on our Sonora Gold property in Sonora, Mexico. The objective of the drill program is to test the continuity of high-grade mineralized shoots nested within vein and vein breccia sets. The program has been specifically designed to better understand the behavior of mineralization at depth and test structures that are thought to be open down dip and on strike. A total of 15 drill holes are initially planned, spread across the three most prospective exploration areas on the property. Targets and scale of the program are subject to change at the direction of management in collaboration with the experienced geological team. Greg Bronson, President of Benjamin Hill Mining Corp. states: "Everyone at Benjamin Hill is anticipati
Mandalay Resources Corporation Announces Production and Sales Results for the Third Quarter of 202119.10.2021 13:30:00 CEST | Press release
TORONTO, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation ("Mandalay" or the "Company") (TSX: MND, OTCQB: MNDJF) announced today its production and sales results for the third quarter of 2021. Third Quarter 2021 Production Highlights: Consolidated saleable gold equivalent production of 33,121 ounces – highest quarterly result since Q4 2017;Consolidated 29,752 ounces of gold equivalent sold – highest quarterly amount in four years;Costerfield’s highest ever quarterly saleable gold equivalent production of 18,946 ounces; andCerro Bayo produced 2,925 ounces of gold equivalent. The Company expects Cerro Bayo’s overall contribution to be 9,000 – 10,000 ounces of gold equivalent by year end. Based on year-to-date production results, Mandalay anticipates that consolidated 2021 saleable production (not including production from Cerro Bayo) will be at the higher end of the previously provided production guidance range of the 105,000 – 117,000 ounces of gold equivalent. Dominic D
EthosEnergy CEO Ana Amicarella recognized as Top Executive for 202119.10.2021 13:00:00 CEST | Press release
San Antonio, Texas, Oct. 19, 2021 (GLOBE NEWSWIRE) -- San Antonio, Texas – EthosEnergy’s CEO, Ana Amicarella has been recognized as Top Executive of the Year during the Experience Power conference hosted by Power magazine. Power magazine honored innovative leaders from the power generation industry during an awards ceremony at the Experience Power conference last night. A worldwide call for nominations went out and submissions were narrowed down to a shortlist of award-worthy contenders into 15 categories. Ana Amicarella, CEO of EthosEnergy said: “I am honored to have won this award. But most of all, I am proud of everything our team has achieved over the last year despite challenging conditions.” Faced with outage cancellations and postponements due to COVID-19, and a depressed oil and gas sector, EthosEnergy’s reaction was to restructure the business to better align with customers and market dynamics. Ana Amicarella was appointed CEO in December 2019 with a mission to take EthosEnerg